Bartlett & Co’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $281K | Sell |
3,466
-800
| -19% | -$62.3K | ﹤0.01% | 427 |
|
|
2023
Q3 | $320K | Sell |
4,266
-417
| -9% | -$32.1K | 0.01% | 394 |
|
|
2023
Q2 | $361K | Buy |
4,683
+950
| +25% | +$75.8K | 0.01% | 383 |
|
|
2023
Q1 | $307K | Buy |
3,733
+509
| +16% | +$42.2K | 0.01% | 341 |
|
|
2022
Q4 | $277K | Hold |
3,224
| – | – | 0.01% | 348 |
|
|
2022
Q3 | $199K | Sell |
3,224
-163
| -5% | -$10.3K | ﹤0.01% | 376 |
|
|
2022
Q2 | $209K | Buy |
3,387
+150
| +5% | +$9.29K | ﹤0.01% | 364 |
|
|
2022
Q1 | $192K | Sell |
3,237
-300
| -8% | -$19.2K | ﹤0.01% | 392 |
|
|
2021
Q4 | $257K | Sell |
3,537
-1,991
| -36% | -$137K | ﹤0.01% | 366 |
|
|
2021
Q3 | $386K | Sell |
5,528
-1,500
| -21% | -$105K | 0.01% | 276 |
|
|
2021
Q2 | $484K | Sell |
7,028
-2,940
| -29% | -$196K | 0.01% | 264 |
|
|
2021
Q1 | $644K | Sell |
9,968
-2,045
| -17% | -$132K | 0.01% | 234 |
|
|
2020
Q4 | $700K | Sell |
12,013
-177,512
| -94% | -$10.7M | 0.01% | 227 |
|
|
2020
Q3 | $12M | Sell |
189,525
-23,360
| -11% | -$1.62M | 0.28% | 74 |
|
|
2020
Q2 | $16.4M | Sell |
212,885
-20,825
| -9% | -$1.6M | 0.43% | 67 |
|
|
2020
Q1 | $17.5M | Buy |
+233,710
| New | +$16.1M | 0.53% | 56 |
|
|
2019
Q3 | $14.8M | Sell |
233,744
-2,910
| -1% | -$190K | 0.39% | 71 |
|
|
2019
Q2 | $16M | Sell |
236,654
-5,086
| -2% | -$335K | 0.6% | 58 |
|
|
2019
Q1 | $15.7M | Buy |
241,740
+29,435
| +14% | +$1.96M | 0.6% | 55 |
|
|
2018
Q4 | $13.3M | Sell |
212,305
-79,563
| -27% | -$5.56M | 0.57% | 56 |
|
|
2018
Q3 | $22.5M | Buy |
291,868
+12
| +0% | +$906 | 0.85% | 44 |
|
|
2018
Q2 | $20.7M | Sell |
291,856
-10,732
| -4% | -$758K | 0.84% | 45 |
|
|
2018
Q1 | $22.8M | Buy |
302,588
+5,699
| +2% | +$453K | 0.94% | 44 |
|
|
2017
Q4 | $21.3M | Sell |
296,889
-5,190
| -2% | -$394K | 0.85% | 49 |
|
|
2017
Q3 | $24.5M | Buy |
302,079
+10,740
| +4% | +$821K | 1.03% | 39 |
|
|
2017
Q2 | $20.6M | Sell |
291,339
-10,264
| -3% | -$683K | 0.93% | 43 |
|
|
2017
Q1 | $20.5M | Sell |
301,603
-4,018
| -1% | -$283K | 0.93% | 40 |
|
|
2016
Q4 | $21.9M | Sell |
305,621
-32,661
| -10% | -$2.43M | 1.03% | 36 |
|
|
2016
Q3 | $26.8M | Buy |
338,282
+3,330
| +1% | +$271K | 1.29% | 31 |
|
|
2016
Q2 | $27.9M | Buy |
334,952
+4,881
| +1% | +$433K | 1.38% | 26 |
|
|
2016
Q1 | $30.3M | Buy |
330,071
+19,495
| +6% | +$1.76M | 1.52% | 20 |
|
|
2015
Q4 | $31.4M | Buy |
310,576
+23,266
| +8% | +$2.42M | 1.62% | 19 |
|
|
2015
Q3 | $28.2M | Buy |
287,310
+8,155
| +3% | +$906K | 1.55% | 22 |
|
|
2015
Q2 | $32.7M | Buy |
279,155
+4,824
| +2% | +$527K | 1.64% | 23 |
|
|
2015
Q1 | $26.9M | Buy |
274,331
+34,556
| +14% | +$3.51M | 1.34% | 27 |
|
|
2014
Q4 | $22.6M | Buy |
239,775
+2,018
| +0.8% | +$209K | 1.09% | 32 |
|
|
2014
Q3 | $25.3M | Sell |
237,757
-9,380
| -4% | -$918K | 1.22% | 30 |
|
|
2014
Q2 | $20.5M | Buy |
247,137
+36,580
| +17% | +$2.85M | 0.99% | 38 |
|
|
2014
Q1 | $14.9M | Buy |
+210,557
| New | +$16.5M | 0.74% | 52 |
|
|
2013
Q4 | – | Sell |
-277
| Closed | -$17K | – | 726 |
|
|
2013
Q3 | $17K | Buy |
+277
| New | +$16.6K | ﹤0.01% | 536 |
|
Other funds holding GILD
Bartlett & Co's GILD Position: Q4 2023 in Review
Bartlett & Co reduced its Gilead Sciences (GILD) stake by 19% in Q4 2023, selling an estimated $62.3K and leaving 3,466 shares worth $281K. The position accounts for ﹤0.01% of the portfolio, ranked #427.
Bartlett & Co first reported a position in GILD in Q3 2013 and has held it in 40 quarters since. The position peaked at $32.7M in Q2 2015. 1,775 funds tracked by Wall St. Rank hold GILD as of Q4 2023.
- Bartlett & Co held 3,466 shares of Gilead Sciences worth $281K as of Q4 2023.
- Bartlett & Co sold 800 Gilead Sciences shares in Q4 2023, an estimated $62.3K.
- Gilead Sciences made up ﹤0.01% of Bartlett & Co's portfolio in Q4 2023, its #427 holding.
- Bartlett & Co first reported a position in Gilead Sciences in Q3 2013 and has held it in 40 quarters since.
- Bartlett & Co's Gilead Sciences position peaked at $32.7M in Q2 2015.
- 1,775 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2023.
Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.